항불안제 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Anti-Anxiety Drug Market size is expected to reach USD 33.58 Billion in 2034 from USD 18.72 Billion (2025) growing at a CAGR of 6.71% during 2026-2034.

The global anti-anxiety drug market has shown steady, single-digit growth driven by rising diagnosis rates of anxiety disorders, broader mental-health awareness, and expanded access to care. Prescription volumes for SSRIs, SNRIs, benzodiazepines alternatives, and newer anxiolytics are increasing, and many markets report mid-single-digit CAGRs through the late 2020s as treatment guidelines evolve and telepsychiatry improves access. Recent market estimates place 2024 valuations in the low double-digit billions with moderate growth projected through 2032. DataBridge Market Research

Key growth drivers include growing public awareness of mental-health conditions, reduced stigma, and expanded reimbursement for psychiatric care. Technological enablers such as telemedicine and digital therapeutics increase treatment adherence and follow-up, boosting pharmaceutical uptake. At the same time, shifting prescribing patterns toward safer, non-sedating agents and demand for combination therapies support steady prescription growth. Emerging markets with improving mental-health infrastructure and aging populations with comorbidities further underpin demand. (Clinical trial activity and patent expiries also reshape competition and pricing dynamics.)

Future prospects look steady but competitive: innovation will center on safer, rapid-acting agents (including biologics and repurposed compounds), personalized medicine approaches, and integration with digital mental-health platforms. Market expansion will be strongest where access increases - telehealth-enabled regions and countries expanding mental-health coverage. Pricing pressures from generics and payer scrutiny will temper margins, pushing firms to differentiate via patient support services and combination offerings. Overall, expect gradual volume growth, modest revenue expansion, and consolidation among mid-sized specialty players.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Drug Class

• Benzodiazepines
• Antidepressants
• Beta-Blockers
• Antihistamines
• Others

By Application

• Generalized Anxiety Disorder
• Panic Disorder
• Social Anxiety Disorder
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others

COMPANIES PROFILED

• Pfizer Inc, Eli Lilly and Company, AstraZeneca, GlaxoSmithKline plc, Johnson Johnson, BristolMyers Squibb Company, Merck Co Inc, Sanofi SA, H Lundbeck AS, Teva Pharmaceutical Industries Ltd, Allergan plc, Sun Pharmaceutical Industries Ltd
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL ANTI-ANXIETY DRUG MARKET: BY DRUG CLASS 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Drug Class
• 4.2. Benzodiazepines Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Antidepressants Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Beta-Blockers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Antihistamines Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL ANTI-ANXIETY DRUG MARKET: BY APPLICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Application
• 5.2. Generalized Anxiety Disorder Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Panic Disorder Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Social Anxiety Disorder Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL ANTI-ANXIETY DRUG MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Distribution Channel
• 6.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Online Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL ANTI-ANXIETY DRUG MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Drug Class
  • 7.2.2 By Application
  • 7.2.3 By Distribution Channel
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Drug Class
  • 7.3.2 By Application
  • 7.3.3 By Distribution Channel
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Drug Class
  • 7.4.2 By Application
  • 7.4.3 By Distribution Channel
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Drug Class
  • 7.5.2 By Application
  • 7.5.3 By Distribution Channel
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Drug Class
  • 7.6.2 By Application
  • 7.6.3 By Distribution Channel
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL ANTI-ANXIETY DRUG INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Pfizer Inc
  • 9.2.2 Eli Lilly And Company
  • 9.2.3 AstraZeneca
  • 9.2.4 GlaxoSmithKline Plc
  • 9.2.5 Johnson & Johnson
  • 9.2.6 Bristol-Myers Squibb Company
  • 9.2.7 Merck & Co. Inc
  • 9.2.8 Sanofi S.A
  • 9.2.9 H. Lundbeck A/S
  • 9.2.10 Teva Pharmaceutical Industries Ltd
  • 9.2.11 Allergan Plc
  • 9.2.12 Sun Pharmaceutical Industries Ltd